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Opinion statement
Urogenital dysfunction is commonly reported in Parkinson’s disease (PD), and history
taking and a bladder diary form the cornerstone of evaluation. The assessment of lower
urinary tract (LUT) symptoms include urinalysis, ultrasonography, and urodynamic studies
and help to evaluate concomitant urological pathologies such as benign prostate enlarge-
ment. Antimuscarinic medications are the first line treatment for overactive bladder (OAB)
symptoms and solifenacin has been specifically studied in PD. Antimuscarininc drugs may
exacerbate PD-related constipation and xerostomia, and caution is advised when using
these medications in individuals where cognitive impairment is suspected. Desmopressin
is effective for the management of nocturnal polyuria which has been reported to be
common in PD. Intradetrusor injections of botulinum toxin have been shown to be
effective for detrusor overactivity, however, are associated with the risk of urinary
retention. Neuromodulation is a promising, minimally invasive treatment for PD-related
OAB symptoms. Erectile dysfunction is commonly reported and first line treatments
include phosphodiesterase-5 inhibitors. A patient-tailored approach is required for the
optimal management of urogenital dysfunction in PD.
Movement Disorders (A Videnovich, Section Editor)
* The Author(s) 2016. This article is published with open access at Springerlink.com
Introduction
Parkinson’s disease (PD) is a progressive neurodegen-
erative disorder characterized by motor complaints of
slowness of movements, resting tremor, and gait im-
balance; however, Bnon-motor symptoms^ are com-
monly reported and have a tremendous impact on
quality of life [1, 2]. Lower urinary tract (LUT) symp-
toms are often reported by patients, either storage
symptoms (urinary urgency, frequency, nocturia, with
or without incontinence) or voiding symptoms (slow
and/or interrupted stream, terminal dribble, hesitan-
cy and straining) [3]. The prevalence of LUT symp-
toms varies according to the study cited and ranges
between 38 and 71 %, being influenced by the stage
of disease and presence of LUT-related comorbidities,
and parallels other manifestations of autonomic dys-
function [4–7]. The presence of LUT symptoms is
associated with an increased risk for falls [8], early
institutionalization and escalating health-related
costs [9]. Nocturia is the most common non-motor
symptom in PD but the causes for nocturia in PD are
poorly understood [10, 11].
Urodynamic studies may demonstrate reduced
bladder capacity, poor compliance and detrusor
overactivity (DO) in 43–93 % of patients of PD
patients [12–14]. A likely mechanism for OAB
symptoms in PD is disruption of the dopamine
D1-GABAergic direct pathway and its GABAergic
collateral to the micturition circuit [15–17],
resulting in loss of inhibition of the micturition
reflex and OAB symptoms. OAB symptoms correlate
in severity with urodynamic abnormalities and do-
paminergic deficit on dopamine transporter scans
[3, 18]. Nocturia additionally may also be due to
nocturnal polyuria, characterized by increased noc-
turnal urine production more than 20–33 % of the
entire 24-h volume [19]. Sexual dysfunction (SD) is
frequently reported in PD and negatively impacts
quality of life of both patients and partners. Men
most commonly experience erectile dysfunction
(ED) and difficulties in ejaculation, and women
report reduced vaginal lubrication, painful inter-
course and incontinence during sexual activity
[20]. Patients may also report alterations in sexual
desire such as hyposexuality or hypersexuality. Mo-
tor symptoms of PD such as tremor, muscle rigidity,
dyskinesia and bradykinesia can affect sexual perfor-
mance and satisfaction [20]. The management op-
tions for bladder and sexual dysfunction are
discussed in this article. This article does not con-
tain any studies with human or animal subjects
performed by any of the authors.
Management of lower urinary tract dysfunction
Despite the high prevalence of LUT symptoms and im-
pact on quality of life, treatment options are currently
limited and are often poorly tolerated or ineffective in
PD. Most treatment options are derived from guidance
around general management of LUT symptoms in neu-
rological patients. Comprehensive history taking is a
sound starting point, as this provides insight into wheth-
er patients have storage dysfunction or voiding dysfunc-
tion, or both. Patients often have other medical comor-
bidities and the medications prescribed for these may
contribute to LUTS, for example, diuretics used for man-
aging hypertension increase urinary urgency and fre-
quency. A review of concomitant medications provides
an opportunity to review a patient’s Banticholinergic
burden^, and adding an antimuscarinic medication
may increase the risk for falls, cognitive impairment
and all-cause mortality [21]. Physical examination in-
volves examining the abdomen, flank and pelvic and
genital organs, and when appropriate, evaluating uro-
genital sensations, sacral cord-mediated reflexes
(bulbocavernosus reflex, anal reflex) and anal sphincter
tone and contractions. Digital rectal examination in a
male patient allows evaluation of the size and consis-
tency of the prostate gland.
The bladder diary, ideally maintained by the patient
or carer for a period of time usually 3 days, provides
prospective information in real-time about LUT symp-
toms about the fluid intake, urine output, time of voids
and recorded indicators of bother and severity of symp-
toms. It is the only evaluation that provides information
about nocturnal polyuria [22••]. Urinalysis (urine dip-
stick test) provides a rapid method of screening for
Urinary tract infections (UTIs) which may share symp-
toms of OAB in the neurological population [23]. Ultra-
sonography is a non-invasive test that evaluates the
lower and upper urinary tract for pathologies such as
stones, hydronephrosis and prostate enlargement and
also provides a measure of the post-void residual urine
[24••, 25, 26••]. Uroflowmetry is a non-invasive
urodynamic study that provides information about
voiding. It can be used to diagnose bladder outflow
obstruction and assess the patient’s flow rate, time and
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pattern. Cystometry is not performed as a routine, how-
ever, may be required to evaluate the cause for LUT
symptoms and exclude concomitant pathologies such
as bladder outlet obstruction (Table 1) [24••, 25, 26••].
Diet and lifestyle
Although there are no studies specifically in PD, lifestyle interventions and
behaviour modifications can improve OAB symptoms in patients with neuro-
logical disorders. Caffeine and/or alcohol should be avoided where possible as
these both have mild diuretic properties. Restricting fluid intake at least 4 h
prior to bedtime may help with nocturia [28]. Absorption of dependent edema
fluid at night may contribute to nocturia, and adequate exercise, lower limb
elevation above the heart level in the afternoon and use of compression
stockings may help address this. The use of diuretics in the late afternoon may
help with nocturia [29]. Emptying the bladder before going to bed is also
advisable. To reduce the risk for falls at night, the path to the toilet should
be well-lit and the area should be made ‘falls safe’ to avoid falls and
injuries. In patients with limited mobility but preserved continence, simple
measures such as using a bedside commode or flask may obviate the need
to walk to the toilet at night [30•].
Pharmacologic treatment
Antimuscarinic agents
& Antimuscarinic agents are the first line treatment for OAB symptoms [31].
These include oxybutynin, tolterodine, solifenacin, darifenacin,
fesoterodine and trospium chloride [27••, 32] (Table 2).
& Antimuscarinic agents competitively antagonize muscarinic acetylcholine
receptors, prevent detrusor contraction, lower intravesical storage pressures
and reduce storage symptoms.
The effect that these medications may have on central muscarinic
receptors has attracted considerable interest in recent years [24••, 33]. The
central effects of these medications may result in alterations in cognition
and consciousness in susceptible individuals. Medications currently being
used by the patient should be reviewed before prescribing an
Table 1. The clinical assessment of urogenital dysfunction in PD (modified from Panicker et al. 2015 [27••])
Bedside evaluation Non-invasive tests Invasive tests
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antimuscarinic agent, especially in older people, as the cumulative use of
agents with anticholinergic properties is associated with increased risk of
cognitive impairment [33]. Permeability across the blood–brain barrier
differs between antimuscarinic agents based upon physicochemical prop-
erties. For example, trospium chloride is a poorly lipophilic, positively
charged quaternary ammonium compound that does not readily cross the
blood–brain barrier and theoretically might be associated with fewer effects
on cognition, though this has not been specifically evaluated in PD [34].
& Muscarinic receptor selectivity may influence central effects. For example,
darifenacin has a greater affinity for the M3 receptor subtype of relevance to
bladder functions compared to the M1 receptors prevalent in the central
nervous system A recent double-blind, randomized, placebo-controlled
study evaluated solifenacin in 23 patients with PD and urinary symptoms.
There was no significant change in themean number ofmicturition per 24 h
Table 2. Drugs used for management of LUT symptoms in PD









7 · 5–15 Once daily NA NA
Fesoterodine-controlled
release
4–8 Once daily NA NA
Oxybutynin Level 1 Level 5
Immediate release 2 · 5–5 Two or three
times a day
Controlled release 5–20 Once daily
Transdermal patch 36 (releasing ∼3 · 9 mg





5–10 Once daily Level 2 Level 2
Tolterodine Level 3 Level 5
Immediate release 2–4 Once or twice daily
Controlled release 4 Once daily
Trospium chloride Level 1 Level 5
Immediate release 20 Twice daily (before
food)
Controlled release 60 Once daily
Other drugs
Mirabegron 25 to 50 mg Once daily NA NA
Desmopressin NA Level 5
Nasal spray 5 to 40 mcg/day Once daily
Tablets 0.1 mg Once daily
Injections 4 mcg/mL Once daily
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period during the double-blind phase, but in the open label extension phase
there was an improvement in the number of micturitions and number of
nocturia episodes per 24 h period at a mean dose of 6 mg/day [35••].
Darifenacin [36]
Standard dosage 7. 5 to 15 mg once daily.
Class of evidence NA [24••, 37]
Contraindications Urinary retention; narrow angle glaucoma; gastric or intestinal obstruction,
severe dementia or myasthenia gravis.
Main drug interactions Preparations containing potassium can increase gastric intolerance, topiramate
or zonisamide can increase chances of heat prostration.
Main side effects Constipation, headache and xerostomia. Other side effects include urinary reten-
tion or tract infection and blurred vision. Anticholinergic central nervous system
(CNS) effects are specifically relevant in elderly and patients with PD dementia.
Special points Safety during pregnancy uncertain [Category C].
Fesoterodine [36]
Standard dosage 4–8 mg once daily.
Class of evidence 5 [24••, 37]
Contraindications Urinary retention; narrow angle glaucoma; gastric or intestinal obstruction,
severe dementia or myasthenia gravis [38].
Main drug interactions Preparations containing potassium can increase gastric intolerance, topiramate
or zonisamide can increase chances of heat prostration.
Main side effects Xerostomia (19–35 %), headache insomnia and constipation. Other side effects
include urinary retention or tract infection and blurred vision. Anticholinergic
CNS effects are specifically relevant in elderly and patients with PD dementia.
Special points Safety during pregnancy uncertain [Category C].
Oxybutinin [36]
Standard dosage Immediate release tablet: 2.55 mg two to three times daily.
Extended release tablets 5–20 mg daily.
Transdermal patch 3.9 mg/day, applied twice weekly (every 3 to 4 days).
Class of evidence Level 5 for urinary dysfunction in PD [11, 37] [level 1 evidence for neurogenic
detrusor overactivity [39]]
Contraindications Urinary retention; narrow angle glaucoma; gastric or intestinal obstruction,
severe dementia or myasthenia gravis [38].
Main drug interactions Preparations containing potassium can increase gastric intolerance, topiramate
or zonisamide can increase chances of heat prostration.
Main side effects Constipation, headache and xerostomia. Other side effects include urinary
retention or tract infection and blurred vision. Anticholinergic CNS effects are
specifically relevant in elderly and patients with PD dementia.
Special points Pregnancy category B.
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Solifenacin [36, 40]
Standard dosage 5–10 mg orally per day
Class of evidence Level 1a for urinary dysfunction in PD [35••] (level 1 evidence for neurogenic
detrusor overactivity [40].
Contraindications Urinary retention; narrow angle glaucoma; liver disease; kidney disease; intes-
tinal obstruction; long QT syndrome.
Main drug interactions Ketoconazole may significantly increase the blood levels of solifenacin, cloza-
pine, citalopram, clarithromycin and other drugs that can prolong QT interval
can increase the risk of arrhythmia with solifenacin
Main side effects Constipation and xerostomia. Other side effects include blurred vision and heat
intolerance.
Special points Safety during pregnancy uncertain [Category C], reduced dose (5 mg/day)
possible in hepatic and renal failure
Tolterodine [36, 38]
Standard dosage 2 mg twice a day or 4 mg extended release capsule
Class of evidence Level 5 for urinary dysfunction in PD [37, 41•] [level 3 evidence for neurogenic
detrusor overactivity [42]]
Contraindications Urinary retention; narrow angle glaucoma; gastric or intestinal obstruction,
severe dementia or myasthenia gravis [38].
Main drug interactions Preparations containing potassium can increase gastric intolerance, topiramate
or zonisamide can increase chances of heat prostration.
Main side effects Constipation, dyspepsia, dizziness and xerostomia. Other side effects
include urinary retention or tract infection and blurred vision. Anticho-
linergic CNS effects are specifically relevant in elderly and patients with
PD dementia.
Special points Safety during pregnancy uncertain [Category C].
Trospium chloride [36, 43]
Standard dosage 20 mg twice a day or 60 mg extended release capsule
Class of evidence Level 5 for urinary dysfunction in PD [24••, 37] [level 1 evidence for neuro-
genic detrusor overactivity [43]]
Contraindications Urinary retention; narrow angle glaucoma; gastric or intestinal obstruction,
severe dementia or myasthenia gravis.
Main drug interactions Preparations containing potassium can increase gastric intolerance, topiramate
or zonisamide can increase chances of heat prostration.
Main side effects Constipation, headache and xerostomia. Other side effects include
urinary retention or tract infection and blurred vision. Anticholinergic
CNS effects are specifically relevant in elderly and patients with PD
dementia.
Special points Safety during pregnancy uncertain [Category C].
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β3-Adrenoceptor agonists
(Mirabegron) [44, 45]
& Recently, mirabegron has emerged as a potentially safe and effective treat-
ment for OAB [44] with preliminary evidence in neurogenic OAB, though
not specifically in PD [45]
& However, high-level evidence supporting the use of mirabegron in the
management of the neurogenic bladder is lacking.
Standard dosage 25 to 50 mg per day
Class of evidence NA [44]
Contraindications Patients with severe uncontrolled hypertension (BP 9 180/110 mmHg) [46]
Main drug interactions Tamoxifen levels may be reduced in patients taking this for breast cancer
Main side effects Worsening of palpitation, preexisting hypertension and urinary retention
Special points Safety during pregnancy uncertain [Category C].
Desmopressin
& Desmopressin, a synthetic analogue of arginine vasopressin, temporarily
reduces urine production and volume-related OAB symptoms.
Desmopressin works by promoting water reabsorption at the distal and
collecting tubules of the kidney. It is useful for the treatment of urinary
frequency or nocturia.
& Desmopressin has been tried in parkinsonism including PD and multiple
system atrophy; however, long-term follow-up is lacking [38, 48, 47•, ].
Standard dosage Nasal spray 5 to 40 mcg/day tablets 0.1 mg, injections 4 mcg/mL
Class of evidence Level 5 [48]
Contraindications Kidney disease, cystic fibrosis, hyponatremia, heart failure and pedal edema.
Used with caution over 65 years of age.
Main drug interactions Antidepressants—citalopram, sertraline and duloxetine can increase chances of
hyponatremia with desmopressin
Main side effects Headache, hyponatremia specifically relevant in patients older than 65.
Special points Safety during pregnancy uncertain [Category C].
Botulinum toxin
Intradetrusor injection of onabotulinumtoxinA has proven to be a safe and
effective treatment for neurogenic DO. In one study of 20 patients with
DO moderate to marked symptom relief at 3 months and a 50 % incon-
tinence decrease over 6 months relative to pretreatment was reported in
59 % patients (p ≤ 0.02) [49••]. Another study of eight patients reported
clinical and urodynamic improvement in overactive bladder symptoms
that lasted at least 6 months in patients with PD [50]. In another study,
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Kulacksizoglu et al. reported no increase in post-voiding residual [51].
OnabotulinumtoxinA treatment results in impaired detrusor contractility
and therefore is associatedwith a risk for urinary retention. The potential benefits
of this treatment must be weighed against the potential need to intermittently
catheterize or use an indwelling catheter, and the accompanying dependence on
carers or partners and possible complications including urinary tract infection,
trauma, bleeding, potential for lower limb weakness and flu-like illness.
Assistive procedures
Clean intermittent self catheterization
The finding of a high post-void residue (PVR) is unusual in patients with PD. If
the PVR volume is consistently more than 100 mL, clean intermittent catheter-
ization has been advocated. Specific issues related to dexterity in PDmay make
this challenging. Experienced health-care professionals, such as a continence
adviser, should be involved in teaching the technique and exploring possible
barriers to successful catheterization. Complications include UTI and trauma
[26••, 52•].
Neuromodulation
& Percutaneous tibial nerve stimulation (PTNS) is an emerging treatment
option that may help patients who have contraindications or are refractory
to medical treatment. Following acute PTNS, the functional bladder ca-
pacity has been shown to be increased [53]. Chronic stimulation has been
reported to decrease frequency, urinary and urge urinary incontinence in
neurogenic bladder, but long term outcomes in PD are lacking [53]
& Transcutaneous tibial nerve stimulation (TTNS) was found effective in the
treatment of LUT symptoms in 13 patients with PD, reducing urgency and
nocturia [54]
& Sacral neuromodulation (SNM)may be effective and safe for the treatment
of patients with neurogenic lower urinary tract dysfunction (LUTD).
However, studies specifically in PD are lacking. A systematic review and
meta-analysis included only four patients with PD and this group was not
separately analysed. [55].
Specific therapies for Parkinson’s disease in management of
urological dysfunction
Dopaminergic treatment
The effects of levodopa on LUT symptoms are variable [3, 56, 57]. There may be
a period of initial worsening after starting levodopa but this may improve later
[3]. One study showed that treatment with levodopa for 3 months in PD
patients was associated with slightly improved storage urodynamic parameters
[3]. In another study, DOwas shown to worsen with levodopa in some patients
and lessened in others. The effect on micturition of treatment with dopaminer-
gic drugs in PD was unpredictable in another study [56]. Dopaminergic drugs
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like bromocriptine can lead to decreased storage parameters and pergolide
improved nocturia in a small study [57].
In an open label study including three patients 12 weeks of treatment with
pergolide improved LUT symptoms and nocturia frequency in all three patients
and an improvement of sleep QOL in two [57].
Deep brain stimulation
DBS (DBS) is a well-accepted treatment option in advanced PD. Deep brain
stimulation can have variable effects on LUT symptoms with worsening reported
in some and improvement in other studies [58, 60, 59••, ]. Although the studies
have not specifically focusedonnocturia, there is evidence that subthalamic nucleus
DBS-treated patients exhibit significantly less nocturia. In a study comparing DBS
(GPi) and other forms of treatment in 107 patients with PD, the overall amount of
urinary symptoms were similar but fewer DBS patients (47 %) complained of
nocturia compared to conventionally treated (88 %) and to apomorphine pump-
treated (66 %) patients [61]. Not only did the patients who had DBS reported less
nocturia (P=0.007) but also they were also less bothered by nocturia (P=0.01)
compared to the other treatment groups, as assessed by the Danish Prostate
Symptom Score (DanPSS) [61]. More studies may be needed to establish definite
correlation and to understand the pathophysiology of this association.
Surgical therapies for bladder outflow obstruction
Benign prostate enlargement is a common cause for bladder outflow obstruc-
tion in middle age and elderly men and is often a contributory factor for LUT
dysfunction in PD. It was widely believed for several years that men with PD
should not undergo prostate surgery because of the high risk of incontinence
[62]. There is some evidence to support transurethral prostate resection for
bladder outflow obstruction in patients with PD. In a study on 23 patients with
PD, TURP was successful in up to 70 %. The risk of de novo urinary inconti-
nence after surgery was reported as minimal [63••].
Management of sexual dysfunction
Management of sexual dysfunction (SD) in patients with PD includes
both behavioural and pharmacological options depending on the nature
of the sexual dysfunction. Behavioural therapy may be used to treat SD,
if considered as a learned maladaptive behaviour [64] and may involve
the use of psychodynamic psychotherapy and cognitive behavioural therapy [64,
65••]. Pharmacological treatment of SD, on the other hand, requires either the
reduction or elimination of drugs interfering with the sexual function or the
introduction of drugs that improves sexual function [64, 65••]. Ultimately,
treatment options for SD may require multidisciplinary input from neurologists
and psychologists for optimum results [64]. Although phosphodiesterase 5
inhibitors (below) are standard treatment option for erectile dysfunction [66],
intracavernosal alprostadil (prostaglandin E2) 1.25–10 μg injections can be used.
The management of hypersexuality as part of an impulse control disorder
includes reduction/stopping of dopamine receptor agonist and practical thera-
peutic strategies including psychological therapies but not limited to
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counselling, psychotherapy, sex, couple and behavioural therapies
[65••]. Hormonal treatment specifically testosterone has been tried in
PD [67].
Sildanefil
Standard dosage 25–100 mg taken 1 h before sexual activity
Class of evidence Level 5
Contraindications Hypotension (blood pressure below 90/50 mmHg)
Main drug interactions Organic nitrates in any form, alpha-blockers and antihypertensives may cause
hypotension.
Main side effects Headache, flushing and dyspepsia. Temporary visual symptoms (mainly
colour-vision disturbances) may occur with higher doses 100 mg
Special points Used once or twice per week.
Tadalafil
Standard dosage 10 mg orally once a day, as needed, prior to sexual activity
Class of evidence Level 5
Contraindications Hypotension (blood pressure below 90/50 mmHg)
Main drug interactions Organic nitrates in any form, alpha-blockers and antihypertensives may cause
hypotension.
Main side effects Headache, flushing and dyspepsia. Temporary visual symptoms (mainly
colour-vision disturbances) may occur with higher doses 100 mg
Special points Used once or twice per week.
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